Serum MicroRNA-27b as a Screening Biomarker for Left Ventricular Hypertrophy.

Publisher: published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute Country of Publication: United States NLM ID: 8214622 Publication Model: eCollection Cited Medium: Internet ISSN: 1526-6702 (Electronic) Linking ISSN: 07302347 NLM ISO Abbreviation: Tex Heart Inst J Subsets: MEDLINE

Original Publication: Houston, TX : published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute, c1982-

Hypertrophy, Left Ventricular/*blood ; MicroRNAs/*blood; Aged ; Biomarkers/blood ; Female ; Humans ; Hypertrophy, Left Ventricular/diagnosis ; Hypertrophy, Left Ventricular/genetics ; Male ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction

MicroRNA-27b (miR-27b) is frequently upregulated in pressure-overloaded hypertrophic hearts. The clinical implications of aberrant circulating miR-27b in the diagnosis and management of left ventricular hypertrophy warrant study. We investigated whether serum miR-27b is a biomarker for left ventricular hypertrophy (LVH). We used stem-loop reverse-transcription quantitative polymerase chain reaction techniques to analyze serum miR-27b levels in 200 hypertensive patients with LVH, 100 hypertensive patients without LVH, and 100 healthy volunteers. We found that serum miR-27b levels were significantly higher in the hypertensive patients with LVH than in the hypertensive patients without LVH and in the healthy volunteers. Upon receiver operating characteristic curve analysis, serum miR-27b had an area under the curve of 0.885 with 91% sensitivity and 73% specificity in distinguishing hypertensive patients with LVH from healthy volunteers ( P =0.021), and an area under the curve of 0.818 with 79.1% sensitivity and 70.3% specificity in distinguishing hypertensive patients with LVH from those without LVH ( P =0.036). We conclude that circulating miR-27b might serve as a specific, noninvasive biomarker in screening for LVH.

Lancet. 2015 Feb 28;385(9970):812-24. (PMID: 25467564)
Cell Physiol Biochem. 2010;26(3):383-94. (PMID: 20798523)
Curr Top Med Chem. 2013;13(2):216-30. (PMID: 23470079)
Science. 2003 Jul 18;301(5631):336-8. (PMID: 12869753)
Curr Opin Genet Dev. 2005 Oct;15(5):563-8. (PMID: 16099643)
Circulation. 2001 Oct 2;104(14):1670-5. (PMID: 11581147)
Blood. 2012 Mar 15;119(11):2679-87. (PMID: 22207734)
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2111-6. (PMID: 18256189)
Circ Res. 2009 Sep 11;105(6):585-94. (PMID: 19679836)
Blood. 2012 Feb 9;119(6):1607-16. (PMID: 22184411)
Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18255-60. (PMID: 17108080)
Am J Pathol. 2007 Jun;170(6):1831-40. (PMID: 17525252)
J Cell Biochem. 2006 Oct 15;99(3):671-8. (PMID: 16924677)
J Biol Chem. 2010 Apr 16;285(16):11846-53. (PMID: 20164187)
Cardiovasc Res. 2011 Jan 1;89(1):98-108. (PMID: 20736237)
Mol Med Rep. 2015 Jul;12(1):105-10. (PMID: 25738504)
Eur Heart J. 2013 Jul;34(28):2108-9. (PMID: 24040671)
Biomed Res Int. 2014;2014:985408. (PMID: 25013816)
Circulation. 2008 Oct 7;118(15):1567-76. (PMID: 18809798)
Circulation. 2007 Jul 17;116(3):258-67. (PMID: 17606841)
Circ Res. 2007 Feb 16;100(3):416-24. (PMID: 17234972)
Cell Res. 2012 Mar;22(3):516-27. (PMID: 21844895)
Biochem Biophys Res Commun. 2009 Dec 11;390(2):247-51. (PMID: 19800867)
Life Sci. 2013 Nov 26;93(23):855-62. (PMID: 24021888)
Am Heart J. 2001 Mar;141(3):334-41. (PMID: 11231428)
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. (PMID: 18663219)
RNA Biol. 2012 Jun;9(6):850-9. (PMID: 22699556)

Keywords: Biomarkers/blood; ROC curve; cardiomyopathy, hypertrophic/genetics; cardiovascular physiologic phenomena/genetics; gene expression regulation; hypertrophy, left ventricular/diagnosis; microRNAs/blood/isolation & purification/physiology; real-time polymerase chain reaction; sensitivity and specificity

0 (Biomarkers)
0 (MIRN27 microRNA, human)
0 (MicroRNAs)

Date Created: 20171226 Date Completed: 20180720 Latest Revision: 20181113

20250114

PMC5737148

10.14503/THIJ-16-5955

29276436